Cardiovascular risk assessment in daily clinical practice: when and how to use a risk score

Germana Panattoni1, Pietro Desimone2, Federica Toto1

  • 1Division of Cardiology, Policlinico Casilino, Via Casilina 1049, 00169 Rome, Italy.

Insights

Cardiovascular disease (CVD) risk scores help identify high-risk patients for better prevention and management. This review guides selecting appropriate CVD risk scores for clinical practice.

Area of Science:

  • Cardiology
  • Preventive Medicine
  • Health Risk Assessment

Background:

  • Cardiovascular diseases (CVDs) are a leading cause of global morbidity and mortality.
  • European Society of Cardiology Guidelines advocate for risk prediction models in managing cardiovascular risk factors and promoting healthy behaviors.
  • Risk models are crucial for identifying high-risk individuals in primary prevention to reduce adverse events and premature deaths.

Purpose of the Study:

  • To review and guide the selection of appropriate cardiovascular disease (CVD) risk scores for diverse clinical practice settings.
  • To highlight the importance of risk stratification in both primary and secondary CVD prevention.
  • To emphasize the integration of conventional and emerging non-traditional markers in CVD risk assessment.

Main Methods:

  • Literature review of current European Society of Cardiology guidelines and risk prediction models.
  • Analysis of the role of CVD risk scores in primary and secondary prevention strategies.
  • Discussion on the incorporation of conventional and non-traditional risk factors into risk stratification.

Main Results:

  • Risk models integrate conventional factors to estimate 10-year CVD risk.
  • Emerging non-traditional markers should be considered alongside conventional factors.
  • Evaluating residual CVD risk is essential for optimal secondary prevention and identifying high-risk patients for intensive management.

Conclusions:

  • Appropriate selection of CVD risk scores is vital for effective patient management and public health.
  • Risk stratification aids in tailoring preventive strategies and intensive treatments for high-risk individuals.
  • This review offers guidance on choosing the most suitable CVD risk score for different clinical scenarios.

Related Concept Videos

Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
261
Pre-Procedural Guidelines for Assessing Blood Pressure01:10

Pre-Procedural Guidelines for Assessing Blood Pressure

Accurate blood pressure assessment is crucial for diagnosing and managing various health conditions. To ensure the reliability of these measurements, healthcare professionals must adhere to standardized pre-procedural guidelines. These guidelines enhance patient safety and improve the overall quality of healthcare. The following steps are essential for obtaining accurate and consistent blood pressure readings, from using the appropriate tools to ensuring effective communication with the...
518
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
81
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
111
Assessment of the Cardiovascular System II: Inspection01:29

Assessment of the Cardiovascular System II: Inspection

Inspection is the initial step in assessing the cardiovascular system. It involves a detailed visual examination that provides crucial information about a patient's circulatory and cardiac health. This systematic process, conducted from head to toe, helps identify signs of cardiovascular conditions by observing physical appearance, skin and mucous membranes, jugular and carotid pulsations, chest symmetry, and the condition of the extremities.
Head and Neck
156
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
41